Notch is out — your watchlist beside the MacBook notch, synced with this account.
Learn more ↗We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
EPS 컨센서스 -0.36 · 매출 컨센서스 12.2만. 발표 후 실제치와 비교하세요.
EPS -0.28 · 매출 24.4만. 세부 수치와 가이던스는 원문에서 확인하세요.
신규 편입 · 포트폴리오 비중 0.00%
US analyst rating / recommendation change.
EPS -0.32 · 매출 25.1만. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $15.21 · 7 analysts
Stored first · Google News · Yahoo Finance (English)
Coya Therapeutics Advances COYA 302 ALS Trial With 100th Participant - Streetwise Reports
Coya Therapeutics Advances COYA 302 ALS Trial With 100th Participant Streetwise Reports
Coya Therapeutics Enrolls 100th Patient in ALSTARS Trial of COYA 302 for ALS - The Clinical Trial Vanguard
Coya Therapeutics Enrolls 100th Patient in ALSTARS Trial of COYA 302 for ALS The Clinical Trial Vanguard
Coya Therapeutics (COYA) Stock Price, News & Analysis - MarketBeat
Coya Therapeutics (COYA) Stock Price, News & Analysis MarketBeat
Coya Therapeutics Hits Enrollment Milestone with 100 Patients in Phase 2/3 ALSTARS ALS Trial - Kalkine Media
Coya Therapeutics Hits Enrollment Milestone with 100 Patients in Phase 2/3 ALSTARS ALS Trial Kalkine Media
Form 8K Coya Therapeutics Inc For: 15 September By Investing.com - Investing.com Nigeria
Form 8K Coya Therapeutics Inc For: 15 September By Investing.com Investing.com Nigeria
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 11. | After market close (AMC) | $-0.36 | — | — | $121.67K | — | Scheduled |
| FY2026 Q2 | 2026. 06. 30. | Time TBD | — | $-0.28 | — | — | $243.75K | Reported |
| FY2026 Q1 | 2026. 03. 31. | Time TBD | — | $-0.32 | — | — | $251.15K | Reported |
| FY2025 Q4 | 2025. 12. 31. | Time TBD | — | — | — | — | $3.96M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 04. 10. | D. Boral Capital | — | Maintain | Buy → Buy | — | D. Boral Capital: Buy |
| 2026. 03. 23. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 03. 20. | D. Boral Capital | — | Maintain | Buy → Buy | — | D. Boral Capital: Buy |
| 2026. 03. 17. | Chardan Capital | — | Maintain | Buy → Buy | — | Chardan Capital: Buy |
| 2026. 03. 17. | D. Boral Capital | — | Maintain | Buy → Buy | — | D. Boral Capital: Buy |
| 2026. 02. 18. | D. Boral Capital | — | Maintain | Buy → Buy | — | D. Boral Capital: Buy |
As of FY2026Q2 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 61,584 | $357.19K | 0.00% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 37,681 | $148.46K | 0.00% | — | New position |
